CRLComplete Response Letter
Complete Response Letter Mesoblast, Inc. (Aug 1, 2023)
FDA's complete response letter contains source-text evidence related to Clinical efficacy and substantial evidence, Statistical analysis, Labeling, packaging, and proprietary name, Chemistry, manufacturing, and controls. Theme counts identify where the letter discusses a topic; they do not replace review of the exact redacted letter.
Issued
US FDA• FDA-regulated product
